Mauri Victor, Frohn Thomas, Deuschl Florian, Mohemed Kawa, Kuhr Kathrin, Reimann Andreas, Körber Maria Isabel, Schofer Niklas, Adam Matti, Friedrichs Kai, Kuhn Elmar W, Scholtz Smita, Rudolph Volker, Wahlers Thorsten C W, Baldus Stephan, Mader Navid, Schäfer Ulrich, Rudolph Tanja K
Heart Center, University of Cologne, Koln, Germany.
Departement of Cardiology, University Hospital Hamburg Eppendorf University Heart Centre, Hamburg, Hamburg, Germany.
Open Heart. 2020 May;7(1). doi: 10.1136/openhrt-2019-001164.
Residual paravalvular regurgitation (PVR) has been associated to adverse outcomes after transcatheter aortic valve replacement (TAVR). This study sought to evaluate the impact of device landing zone (DLZ) calcification on residual PVR after TAVR with different next-generation transcatheter heart valves.
642 patients underwent TAVR with a SAPIEN 3 (S3; n=292), ACURATE (NEO; n=166), Evolut R (ER; n=132) or Lotus (n=52). Extent, location and asymmetry of DLZ calcification were assessed from contrast-enhanced CT imaging and correlated to PVR at discharge.
PVR was ≥moderate in 0.7% of S3 patients, 9.6% of NEO patients, 9.8% of ER patients and 0% of Lotus patients (p<0.001), and these differences remained after matching for total DLZ calcium volume. The amount of DLZ calcium was significantly related to the degree of PVR in patients treated with S3 (p=0.045), NEO (p=0.004) and ER (p<0.001), but not in Lotus patients (p=0.698). The incidence of PVR ≥moderate increased significantly over the tertiles of DLZ calcium volume (p=0.046). On multivariable analysis, calcification of the aortic valve cusps, LVOT calcification and the use of self-expanding transcatheter aortic valve implantation (TAVI) prostheses emerged as predictors of PVR.
The susceptibility to PVR depending on the amount of calcium was mainly observed in self-expanding TAVI prostheses. Thus, DLZ calcification is an important factor to be considered in prosthesis selection for each individual patient, keeping in mind the trade-off between PVR reduction, risk of new pacemaker implantation and unfavourable valve ha emodynamics.
瓣周残余反流(PVR)与经导管主动脉瓣置换术(TAVR)后的不良预后相关。本研究旨在评估不同新一代经导管心脏瓣膜在TAVR后,装置着陆区(DLZ)钙化对残余PVR的影响。
642例患者接受了SAPIEN 3(S3;n = 292)、ACURATE (NEO;n = 166)、Evolut R(ER;n = 132)或Lotus(n = 52)瓣膜的TAVR治疗。通过对比增强CT成像评估DLZ钙化的范围、位置和不对称性,并与出院时的PVR进行关联分析。
S3组患者中0.7%的PVR≥中度,NEO组为9.6%,ER组为9.8%,Lotus组为0%(p<0.001),在匹配总DLZ钙含量后,这些差异仍然存在。DLZ钙含量与接受S3(p = 0.045)、NEO(p = 0.004)和ER(p<0.001)治疗患者的PVR程度显著相关,但与Lotus组患者无关(p = 0.698)。PVR≥中度的发生率随着DLZ钙含量三分位数的增加而显著升高(p = 0.046)。多变量分析显示,主动脉瓣叶钙化、左心室流出道钙化以及使用自膨胀式经导管主动脉瓣植入(TAVI)假体是PVR的预测因素。
PVR对钙含量的易感性主要在自膨胀式TAVI假体中观察到。因此,DLZ钙化是为每个患者选择假体时需要考虑的重要因素,要牢记在降低PVR、新起搏器植入风险和不利瓣膜血流动力学之间进行权衡。